Safety and Efficacy of Low Dose Hypertonic Saline Solution and High Dose Furosemide for Congestive Heart Failure

Congestive Heart Failure Clinical Trial

— REaCH  

Official title:

Assessing the Renal Consequences and Functional Efficacy of Low Dose Hypertonic Saline Solution and Furosemide for the Treatment of Congestive Heart Failure in a Randomized, Double Blind, Prospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01028170
• Other study ID #: REaCH-23.07.09
• Status: Completed
• Phase: Phase 3
• First received: November 27, 2009
• Last updated: February 8, 2012
• Start date: November 2009
• Est. completion date: January 2012

Study information

• Verified date: February 2012
• Source: Aspirus Heart and Vascular Institute-Research and Education
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare high dose furosemide in combination with low volume hypertonic saline solution (2.4%) with intermittent pulse dose furosemide in patients with pre treatment kidney function impairment. The hypothesis is that it will provide effective diuretic response and have a beneficial effect on preservation of renal function as compared to pulse furosemide in patients with pre-treatment renal impairment (GFR < 60 mL/min).

Description:

Currently, congestive heart failure (CHF) is the fastest growing heart-related diagnosis in North America, with the chance of a person experiencing it during their lifetime around 20%. In patients with CHF, acute decompensation requiring hospitalizations are common. Patients with renal insufficiency are more susceptible to worsening of renal function or overt renal failure in relation to an episode of decompensated heart failure. Thus, there is a great need for treatment to help patients with renal dysfunction that can simultaneously protect them from further renal deterioration. Preliminary evidence indicates that hypertonic saline solution (HSS) combined with high dose loop diuretics may improve the prognosis for patients with CHF. In two separate studies, this treatment was found to alleviate symptoms of CHF, and significantly reduce hospital length of stay, as well as reduce morbidity and mortality subsequent to hospital stay. So far, available studies have demonstrated that renal function is not compromised when using HSS and high dose furosemide as a treatment for CHF. Preliminary data from our institution suggests that low volume HSS combined with high dose furosemide may be beneficial for patients with renal insufficiency.

Hypothesis:

High dose furosemide in combination with low volume HSS provides effective diuretic response and has a beneficial effect on preservation of renal function while in hospital as compared to pulse furosemide in patients with pre-treatment renal impairment (GFR < 60 mL/min).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: January 2012
• Est. primary completion date: July 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Uncompensated CHF

• Framingham Criteria for HF

• 2 Major or

• 1 Major 2 minor

Major criteria:

• Paroxysmal nocturnal dyspnea

• Neck vein distention

• Rales

• Radiographic cardiomegaly (increasing heart size on chest radiography)

• Acute pulmonary edema

• S3 gallop

• Increased central venous pressure (>16 cm H2O at right atrium)

• Hepatojugular reflux

• Weight loss > 4.5 kg in 5 days in response to treatment

Minor criteria:

• Bilateral ankle edema

• Nocturnal cough

• Dyspnea on ordinary exertion

• Hepatomegaly

• Pleural effusion

• Decrease in vital capacity by one third from maximum recorded

• Tachycardia (heart rate>120 beats/min.)

• No Ejection Fraction Inclusion Criteria

• GFR £ 60 mL/min

• GFR (mL/min/1.73 m2) = 186 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African American) (conventional units).

• Informed consent

Exclusion Criteria:

• Patients with Acute Coronary Syndrome

• Post -op patients within 90 days of previous surgery

• Patients currently on dialysis

• Hospice patients

• Patients < 18 years of age.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Congestive Heart Failure
• Heart Failure
• Renal Insufficiency

Intervention

Drug:
• furosemide and hypertonic saline solution
250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
• furosemide
80-160 mg furosemide (Given over 5 min IV twice a day)

Locations

Country	Name	City	State
United States	Aspirus Wausau Hospital	Wausau	Wisconsin

Sponsors (2)

Lead Sponsor	Collaborator
Aspirus Heart and Vascular Institute-Research and Education	Aspirus Wausau Hospital

Country where clinical trial is conducted

United States, 

References & Publications (5)

Lapman PG, Golduber GN, Le Jemtel TH. Heart failure treatment and renal function. Am Heart J. 2004 Feb;147(2):193-4. — View Citation

Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, Argano C, Tuttolomondo A, Paterna S. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003 Mar;145(3):459-66. — View Citation

MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, Redpath A, Pell JP, McMurray JJ. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 2000 Sep 5;102(10):1126-31. — View Citation

Paterna S, Di Pasquale P, Parrinello G, Fornaciari E, Di Gaudio F, Fasullo S, Giammanco M, Sarullo FM, Licata G. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol. 2005 Jun 21;45(12):1997-2003. — View Citation

Paterna S, Parrinello G, Amato P, Dominguez L, Pinto A, Maniscalchi T, Cardinale A, Licata A, Amato V, Licata G, Di Pasquale P. Tolerability and efficacy of high-dose furosemide and small-volume hypertonic saline solution in refractory congestive heart failure. Adv Ther. 1999 Sep-Oct;16(5):219-28. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Renal function (GFR)		30 days	Yes
Secondary	Diuretic response (defined as achievement of weight within 2% of previously determined dry body weight or reaching a clinically compensated state including return of functional level to prior NYHA class as determined by the primary treating physician)		one week	No
Secondary	Length of hospital stay		30 days	No
Secondary	Readmission rate		6 months	No
Secondary	Weight loss		one week	No
Secondary	BNP Levels		discharge, 30 days and 6 months	No
Secondary	Hospitalization cost analysis		30 days	No